T

Tr1X

Develops cellular immunotherapies for autoimmune diseases

Director, Clinical Operations

Full-TimePosted on 10/23/2026
$210k - $230k+ Discretionary annual target bonus + Incentive stock options
Expert
Bachelor's
San Diego, CA, USA
In PersonBased on-site in San Diego; travel required up to 15%.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree in a scientific or healthcare-related discipline and at least 10 years of progressive clinical operations experience, including at least 5 years of direct sponsor clinical study management and leadership experience.
  • Demonstrated leadership experience managing complex global or multi-center clinical trials across multiple phases of development.
  • Extensive working knowledge of ICH/GCP guidelines, FDA regulations, and global clinical trial regulatory requirements.
  • Ability to lead cross-functional teams, influence stakeholders, and drive strategic clinical operations initiatives in a fast-paced environment.
  • Strong operational leadership skills and demonstrated expertise in study start-up, trial execution, vendor oversight, risk management, and inspection readiness.
  • Experience supporting pre-NDA programs and Phase 1 first-in-human clinical trials, including operational strategy, study oversight, monitoring, and close-out activities.
  • Advanced experience with clinical trial systems including eTMF, CTMS, EDC, safety databases, and other clinical technologies.
  • Ability to independently manage competing priorities while leading within a matrixed cross-functional organizational structure.
  • Legally authorized to work for any employer in the United States.
  • Ability to travel up to 15%; the position is based on-site in San Diego, California.
Responsibilities
  • Provide strategic leadership as the Clinical Study Lead for cross-functional teams, ensuring study start-up, enrollment, maintenance, and close-out activities are completed on schedule, within budget, and in accordance with quality expectations.
  • Direct and oversee clinical study management to ensure operational excellence, inspection readiness, and delivery of high-quality clinical data.
  • Lead the clinical operational development, review, and finalization of clinical trial protocol synopses, protocols, protocol amendments, and other key study-related documents.
  • Lead CRO and vendor selection strategy for outsourced activities, including RFP development, bid management, proposal evaluation, budget negotiations, and executive-level vendor selection decisions.
  • Direct negotiation, execution, and oversight of contracts and scopes of work with CROs, study vendors, consultants, and investigative sites.
  • Oversee development and maintenance of critical study documents, including informed consent templates, management plans, study trackers, and operational plans, with appropriate delegation and accountability.
  • Chair and lead internal and external clinical study meetings, governance reviews, and cross-functional operational discussions, ensuring alignment of objectives, decisions, and action items.
  • Partner with Regulatory Affairs to ensure timely preparation and submission of site essential regulatory documentation to the FDA and other regulatory authorities.
  • Develop and oversee clinical monitoring strategies and monitoring plans to ensure compliance, quality oversight, and operational consistency across studies and vendors.
  • Provide strategic oversight for case report form (CRF) design, edit check development, and data collection methodologies in partnership with Data Management and Clinical Development.
  • Lead site initiation planning and execution, including oversight of training materials, presentations, and investigator engagement strategies.
  • Provide leadership and governance oversight of CROs, field monitors, and clinical vendors to ensure contractual obligations, quality metrics, and operational deliverables are achieved.
  • Establish oversight processes for monitoring visit reports, protocol deviations, CAPAs, and action item resolution to maintain quality and compliance standards.
  • Direct study-wide operational activities including vendor management, biospecimen handling, investigational product logistics, investigator payments, data quality oversight, and centralized records management.
  • Lead review and analysis of clinical data reports to identify operational, safety, and efficacy trends, and communicate findings to cross-functional leadership and governance committees.
  • Ensure Trial Master File (TMF) oversight and inspection readiness throughout assigned studies.
  • Lead and facilitate internal clinical program meetings, investigator meetings, safety review committees, and other cross-functional governance forums.
  • Partner with departmental leadership to define and execute clinical development operational strategies, resource planning, and process optimization initiatives.
  • Identify operational risks and implement mitigation strategies to ensure study continuity, compliance, and successful execution.
  • Foster accountability, collaboration, operational excellence, and continuous improvement within the clinical development environment.
  • Perform additional strategic and operational responsibilities as required to support evolving business and clinical development objectives.
Desired Qualifications
  • Experience in cell and/or gene therapy clinical trials, particularly within Multiple Sclerosis, Inflammatory Bowel Disease, or other autoimmune indications.

About the company

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company Size

11-50

Company Stage

Early VC

Total Funding

$125M

Headquarters

San Diego, California

Founded

2018

Get referred to Tr1X

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CIRM approved more than $60 million on June 25, 2026, supporting Tr1X programs.
  • October 14, 2025 financing added $50 million and runway into 2027.
  • ASGCT 2026 oral presentations signaled continued clinical momentum across GvHD, Crohn's, and MS.

What critics are saying

  • TRX103 and TRX319 remain unapproved; FDA efficacy scrutiny arrives before 2027.
  • Crohn's results from NCT06721962 report by January 30, 2027, or credibility slips.
  • No approved product means CIRM and venture cash fund only clinical execution.

What makes Tr1X unique

  • TRX103 delivered dose-dependent persistence and tolerogenic signals at ASGCT 2026.
  • TRX319 combines CD19 targeting with Tr1 regulation for progressive multiple sclerosis.
  • Maria Grazia Roncarolo's Tr1 platform creates off-the-shelf allogeneic regulatory T-cell products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • 401(k) Company Match
  • Flexible Work Hours
  • Stock Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

4%

1 year growth

2%

2 year growth

2%
San Diego Business Journal
Oct 27th, 2025
Tr1X Bio Secures $50M Funding

Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.

GlobeNewswire
Oct 14th, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...

Clinical Trial Vanguard
Apr 7th, 2025
TR1X Awarded $8M Grant for TRX103 GvHD Trial

TR1X awarded $8M grant for TRX103 GvHD trial.

Benzinga
Apr 4th, 2025
Tr1X Awarded $8 Million Cirm Grant To Support Trx103 Phase 1/2A Clinical Trial For Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025

TMCnet
Apr 4th, 2025
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.